Johns Hopkins Researchers Call for Rescheduling Psilocybin
Researchers push to move psilocybin from Schedule I to Schedule IV if Phase III clinical trials are successful.
Researchers push to move psilocybin from Schedule I to Schedule IV if Phase III clinical trials are successful.
The FDA will work to expedite the development and review of the drug so it can get to patients as soon as possible.
Researchers measured the effects of psilocybin in depressed people by comparing brain scan data.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.